{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:36:22Z","timestamp":1790217382706,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Ophthalmologica"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>The primary endpoint results from the comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity (CARE\u2010ROP) core study identified ranibizumab as an effective treatment to control acute retinopathy of prematurity (ROP). This study reports the 1\u2010 and 2\u2010year follow\u2010up data focusing on long\u2010term functional outcomes and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The CARE\u2010ROP trial compared 0.12\u2009mg versus 0.20\u2009mg ranibizumab in 20 infants with ROP in a multicentric, prospective, randomized, double\u2010blind, controlled study design. Sixteen patients entered the follow\u2010up period. An ophthalmologic assessment at one year postbaseline was acquired from all 16 patients and a neurodevelopmental assessment at two years postbaseline was acquired from 15 patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifteen of 16 infants were able to fixate and follow moving objects at one year postbaseline treatment. One child progressed to stage 5 ROP bilaterally between the end of the core study and the 1\u2010year follow\u2010up (first seen at PMA 75\u2009weeks). Mean spherical equivalents were \u22121.9 diopters (D) and \u22120.75 D in the 0.12\u2009mg and the 0.20\u2009mg treatment arms. Strabismus was present in seven and nystagmus in five out of 16 infants. Mental development scores were within normal limits in six out of ten patients with available data. No statistically significant difference was observed between the two treatment arms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Neurodevelopmental and functional ocular outcomes 1 and 2\u2009years after treatment with ranibizumab are reassuring regarding long\u2010term safety. Late reactivation of ROP, however, represents a challenge during the follow\u2010up phase and it is of utmost importance that regular follow\u2010ups are maintained.<\/jats:p><\/jats:sec>","DOI":"10.1111\/aos.14852","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T06:10:35Z","timestamp":1616220635000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Ranibizumab in retinopathy of prematurity \u2013 one\u2010year follow\u2010up of ophthalmic outcomes and two\u2010year follow\u2010up of neurodevelopmental outcomes from the CARE\u2010ROP study"],"prefix":"10.1111","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8013-7597","authenticated-orcid":false,"given":"Andreas","family":"Stahl","sequence":"first","affiliation":[{"name":"Department of Ophthalmology University Medicine Greifswald Greifswald Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Christine","family":"Br\u00fcnder","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology University Medicine Greifswald Greifswald Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3558-5905","authenticated-orcid":false,"given":"Wolf A.","family":"Lagr\u00e8ze","sequence":"additional","affiliation":[{"name":"Eye Center Medical Center Faculty of Medicine University of Freiburg Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanni E.","family":"Moln\u00e1r","sequence":"additional","affiliation":[{"name":"Eye Center Medical Center Faculty of Medicine University of Freiburg Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Barth","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology University of Regensburg Regensburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Eter","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology University of Muenster Medical Center Muenster Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Guthoff","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Faculty of Medicine University of Dusseldorf Dusseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim U.","family":"Krohne","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Faculty of Medicine University Hospital Cologne University of Cologne Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2731-6094","authenticated-orcid":false,"given":"Johanna M.","family":"Pfeil","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology University Medicine Greifswald Greifswald Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the CARE\u2010ROP Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_2115_18"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/pr.2013.205"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep27082"},{"key":"e_1_2_5_5_1","unstructured":"Deutsche Ophthalmologische Gesellschaft e.\u202fV. (DOG) Retinologische Gesellschaft e.\u202fV. (RG) & Berufsverband der Augen\u00e4rzte Deutschlands e.\u202fV. (BVA)(2020 May):Stellungnahme von DOG RG und BVA zur Anti\u2010VEGF\u2010Therapie der Fr\u00fchgeborenenretinopathie; ROP\u2010Pass\u2010Formular zum Download. Available at:https:\/\/www.dog.org\/wp\u2010content\/uploads\/2013\/03\/ROPPass_Version\u20103_4_FORMULAR.pdf. (Accessed on 15 Mar 2021)."},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2019-317418"},{"key":"e_1_2_5_7_1","unstructured":"EMA.Europa.eu(2020 January 28):Lucentis 10 mg\/ml solution for injection SmPC. Available at:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/lucentis\u2010epar\u2010product\u2010information_en.pdf. (Accessed on 15 Mar 2021)."},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.2772"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.12760"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.5935\/0004-2749.20150079"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.01.014"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2012.02469.x"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2012.592"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.12.017"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2014.10.027"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2017.10.006"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.04.023"},{"key":"e_1_2_5_18_1","first-page":"464","article-title":"Long\u2010term effects of anti\u2010VEGF therapy for retinopathy of prematurity","volume":"115","author":"Krohne TU","year":"2018","journal-title":"Ophthalmol Z Dtsch Ophthalmol Ges"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-018-0685-6"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002663"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-20680"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.04.028"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3218"},{"key":"e_1_2_5_24_1","first-page":"365","article-title":"Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone","volume":"101","author":"Mueller B","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2015.01.027"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129383"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/EB.S94436"},{"issue":"327","key":"e_1_2_5_28_1","first-page":"e1","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato T","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2017.4838"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31344-3"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(42)92088-9"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13069"},{"key":"e_1_2_5_33_1","first-page":"476","article-title":"Treated cases of retinopathy of prematurity in Germany: 5\u2010year data from the Retina.net ROP registry","volume":"115","author":"Walz JM","year":"2018","journal-title":"Ophthalmol Z Dtsch Ophthalmol Ges"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000578"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.14852","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/aos.14852","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.14852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T04:39:52Z","timestamp":1693111192000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aos.14852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1111\/aos.14852"],"URL":"https:\/\/doi.org\/10.1111\/aos.14852","archive":["Portico"],"relation":{},"ISSN":["1755-375X","1755-3768"],"issn-type":[{"value":"1755-375X","type":"print"},{"value":"1755-3768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]},"assertion":[{"value":"2020-10-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}